
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings is a digital healthcare company that has a positive outlook, supported by their expanding business of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow quicker and more efficient diagnosis. Q1 2026 results showed revenue growth of 26% y/y with plans to launch Zio MCT and Gen 3 algorithm in 1H27 and potential savings of over $100M. Although there are risks such as delays to product launches and potential impacts from regulatory actions, we believe the company's durable revenue growth profile and potential for profitability make it a Buy with a $185 price target based on a ~6x projected 12-24 month revenue estimate.
Bears say
iRhythm Holdings is heavily reliant on a successful launch of their Zio MCT product, which has been delayed several times. With only 53% of accounts being EHR integrated, there is limited potential for widespread adoption in the near term, making it difficult for revenues to catch up with their high operating expenses. Additionally, despite their 2026 Guidance anticipating only 17-18% revenue growth and low double digit EBITDA margins, the company's current valuation is not justified, as it is trading at a much higher multiple compared to its peers in the digital healthcare industry.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares